NeuroPace Is Maintained at Overweight by JP Morgan

Dow JonesDec 18 01:32 · Ratings

J.P. Morgan Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $14

Futu NewsDec 17 19:31 · Ratings

NeuroPace: Undervalued Innovator in the Drug-Resistant Epilepsy Market With Promising Long-Term Growth

TipRanksDec 17 18:37

Express News | Neuropace Inc : JP Morgan Raises Target Price to $14 From $9

BreakingsDec 17 13:27

NeuroPace to Host Investor Day on January 28th in New York City

GlobeNewswireDec 13 05:05

Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20

Futu NewsDec 6 00:31 · Ratings